CAS: 19216-56-9; Prazosin

该化合物是主要用于治疗高血压和良性先天性高血压症状的选择性甲型-1肾上腺激素对抗者,通过阻塞血管滑动肌肉上的甲型-1受体,导致血管通气和血压下降; Prazosin通常通过口服施用,其半衰期相对较短,需要全日多剂量才能持续发挥作用; 众所周知,该化合物能够减少外围抗药性,改善前列腺扩大患者的尿液流动; 此外,还研究了其在治疗创伤后应激障碍(PTSD)方面的潜在好处,因为它对减少噩梦和改善睡眠质量的影响; Prazosin 通常具有良好的缓解作用,尽管它可能会造成副作用,如眩晕,头痛和或霍瑟性低效,特别是在开始治疗时. 其化学结构包括一个五氯线环,有助于其药性. 与任何药物一样,病人都有必要咨询保健专业人员进行适当的剂量和监测.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号57200-93-8 ethyl 4-(2-furo... | CAS号26961-27-3 2-氨基-4,5-二甲氧基苯腈 | CAS号65679-29-0 4-(4-amino-6,7-... | CAS号65679-30-3 4-amino-2-(4-et... | CAS号527-69-5 糠酰氯 | CAS号60547-97-9 2-(1-哌嗪基)-4-氨基-... | CAS号23680-84-4 4-氨基-2-氯-6, 7-二氧基喹唑啉

合成工艺路线路线简述

    📜4-Amino-2-(4-Ethoxycarbonyl-1-Piperazinyl)-6,7-Dimethoxy-Quinazoline 以 乙醚,水 用作溶剂,化学反应生成哌唑嗪
    参考文献:Process For Preparing Hypotensive
    标题:Process For Preparing Hypotensive
    摘要:某些2-(4-芳酰基哌嗪-1-基)-4-氨基-6,7-二甲氧基喹唑啉是通过一种新颖的方法制备的,在该方法中,某些2-(4-取代哌嗪-1-基)-4-氨基-6,7-二甲氧基喹唑啉中间体,其中所述取代基为氰基,某些含碳氧双键基团或某些含碳氮双键基团,与某些金属芳基化合物反应,然后进行水解.这些产物是已知的降压药物.该方法的某些中间体是新颖化合物.

    海关参考信息

    专利信息


    专利号:US-9353057-B2
    优先权日:2003-12-30
    标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
    发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
    权利人:XENOPORT INC
    摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-10973847-B2
    优先权日:2017-06-30
    标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
    发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

    专利号:US-12264143-B2
    优先权日:2020-12-17
    标 题:Synthesis of cannabinoids and cannabinoid precursors, and related compounds, formulations, and methods of use
    发明人:SAMMIS GLENN M; ROGGEN MARKUS
    权利人:NALU BIO INC
    摘要:Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

    专利号:US-9765027-B2
    优先权日:2014-08-22
    标题 :Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
    发明人:VARDANYAN RUBEN S; HRUBY VICTOR J
    权利人:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZAONA; UNIV ARIZONA
    摘要:The invention provides compounds that bind with high affinities to the μ-, δ- and κ-opioid receptors and α 2 -adrenoreceptor. In addition to providing these compounds with novel pharmacological binding properties, the invention also describes detailed novel methods for the preparation of representative compounds and a scheme for the synthesis of related compounds that bind to the opioid receptors and/or α 2 -adrenoreceptor.

    专利号:WO-9614060-A1
    优先权日:1994-11-04
    标题 :Use of receptor agonists to stimulate superoxide dismutase activity
    发明人:MARKLUND STEFAN L; STRAALIN PONTUS
    权利人:MARKLUND STEFAN L; STRAALIN PONTUS
    摘要:The present invention relates to the use of a substance for the manufacture of a composition for stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells. In particular, the invention relates to the use of a substance for the manufacture of a composition for prophylaxis or treatment of a disease or disorder connected with the presence or formation of superoxide radicals and other toxic intermediates derived from the superoxide radical. Further, the invention relates to a method for determining the effect of a substance with respect to stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells and to substances which have been selected by said method. Within the scope of the invention is a method of preventing, diminishing, controlling or inhibiting a disease or disorder connected with the presence or formation of superoxide radicals and other toxic intermediates derived from the superoxide radical in a patient who has been established to have a high risk of developing a such disease or disorder, or who has developed a such disease or disorder, the method comprising administering an effective amount of a substance which is capable of stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1111/j.1476-5381.2011.01591.x
    摘要:Nishimune A, Yoshiki H, Uwada J, Anisuzzaman A, Umada H, Muramatsu I. Phenotype pharmacology of lower urinary tract α1‐adrenoceptors. British J Pharmacology. 2012 Feb 10;165(5):1226–34. doi: 10.1111/j.1476-5381.2011.01591.x.
    参考文献:10.1016/j.ejphar.2011.06.026
    摘要:Ishizuka T, Watanabe Y. α₁-Adrenoceptor stimulation enhances leukemia inhibitory factor-induced proliferation of mouse-induced pluripotent stem cells. Eur J Pharmacol. 2011 Oct 01;668(1-2):42–56. doi: 10.1016/j.ejphar.2011.06.026.
    参考文献:10.1016/j.appet.2011.06.017
    摘要:Mansur SS, Terenzi MG, Marino Neto J, Faria MS, Paschoalini MA. Alpha1 receptor antagonist in the median raphe nucleus evoked hyperphagia in free-feeding rats. Appetite. 2011 Oct;57(2):498–503. doi: 10.1016/j.appet.2011.06.017.
    参考文献:10.4061/2011/417594
    摘要:Demede M, Pandey A, Innasimuthu L, Jean-Louis G, McFarlane SI, Ogedegbe G. Management of Hypertension in High-Risk Ethnic Minority with Heart Failure. International Journal of Hypertension. 2011;2011():1–8. doi: 10.4061/2011/417594.
    摘要:He J, He Q. [Effects of prazosin on the proliferation and apoptosis of K562 leukemia cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005 Oct;30(5):562–5.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知